Literature DB >> 11796304

Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel.

Brandon M Hayes-Lattin1, Peter A Kovach, W David Henner, Tomasz M Beer.   

Abstract

Reports of malignant pericardial effusion due to adenocarcinoma of the prostate are few and describe only patients with hormone-naive disease. We report a case of malignant pleural and pericardial effusions due to metastatic hormone-refractory prostate cancer. Despite presenting with pericardial tamponade, this patient was successfully treated with pericardiocentesis and intrapericardial methylprednisolone and cisplatin, followed by a course of intravenous docetaxel. The patient was alive and free of disease-related symptoms nearly 2 years later. This case suggests that patients with pericardial tamponade due to hormone-refractory prostate cancer do not have a uniformly dismal prognosis and should be considered for aggressive treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796304     DOI: 10.1016/s0090-4295(01)01481-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

1.  Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer.

Authors:  Tomonori Minagawa; Yasushi Murata; Shinichiro Uchikawa; Takeshi Uehara
Journal:  Int J Clin Oncol       Date:  2010-02       Impact factor: 3.402

2.  Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.

Authors:  Yi Lu; Xiongwen Zhang; Ben Beheshti; Jun Zhang
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.